1. No category

3rd of March 2015
ROOM
PANORAMA A+B
08.00
Registration & Coffee
08.20
Welcome Speech
08.30
Public Markets and M&A Panel
Chaired by:
Stephanie Léouzon, Principal and Head of Torreya Partners Europe, Torreya Partners (Europe) LLC
Featuring:
Chandra Leo, Partner, HBM Partners AB
Jim Phillips, Chief Executive Officer, Midatech Group
Nicolas Franco, Executive Vice President & Chief Business Development Officer, Actelion Pharmaceuticals
09.15
Investment Panel
Chaired by:
Tim Haines, Partner, Abingworth LLP
Featuring:
Arthur Franken, Partner, Gilde Healthcare
Bethan Hughes, Senior Business Analyst, Welcome Trust
Graziano Seghezzi, Partner, Sofinnova Partners AS
Graeme Martin, President and CEO, Takeda Ventures, Inc.
Heinz Schwer, CEO, Lanthio Pharma
Jeanne Bolger, Vice President Venture Investments, Johnson & Johnson Innovation
Lionel Carnot, Managing Director, Bay City Capital LLC
Margarita Chavez, Director, Ventures & Early Stage Collaborations, AbbVie Biotech Ventures, Inc.
Markus Goebel, Partner, Novartis Venture Funds
Mirko Scherer, Managing Director, MPM Capital
Olivier Litzka, Partner, Life Sciences, Edmond de Rothschild Investment Partners
10.15
Coffee Break
ROOM
PANORAMA A
10.30
Oncology I & II
Co-chaired by:
Francois Thomas, Managing Director, Thomas Conseil SPRL
Tim Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZeneca
Featuring:
Anja König, Managing Director, Novartis Venture Fund
Anna Davydova, Business Development Director, OCT - Clinical Trials
Anne Altmeyer, Vice President, Business Development & Licensing, Oncology, Novartis Pharmaceuticals
Bernhard Sixt, President & CEO, ImmunID
Carles Domenach, CEO, Ability Pharmaceuticals
Frans Wuite, President & Chief Executive Officer, Oncos Therapeutics
PANORAMA B
Autoimmune & Inflammatory
Co-chaired by:
Chris Maggos, Independent Consultant
Regina Hodits, General Partner, Wellington Partners
Featuring:
Adrian Mills, CBO, Novimmune SA
Dinesh Patel, President & Chief Executive Officer, Protagonist Inc.
Kia Motesharei, Head, Immunology Licensing, EMD Serono
Lothar Steidler, Vice President Technology, Actogenix NV
Onno van de Stolpe, Chief Executive Officer, Galapagos
Simon Kerry, CEO, Karus Therapeutics Ltd
11.15
Oncology I & II
Co-chaired by:
Francois Thomas, Managing Director, Thomas Conseil SPRL
Tim Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZeneca
Featuring:
Guillaume Vignon, Director BD Oncology – Global Business Development and Licensing, EMD Serono
Hamza Suria, President & CEO, AnaptysBio, Inc.
Jakob Lindberg, CEO, Oncopeptides AB
Mike Khan, CMO, Silence Therapeutics
Stephen Sands, Commercial Lead, Oncology/Immunology, F. Hoffmann La Roche AG
Thilo Schroeder, Partner, Nextech Venture
12.00
Neuroscience Panel
Chaired by:
Alethia De Leon, Global BD&L, Head Search & Evaluation Neuroscience and Ophthalmic, Novartis Pharma AG
Featuring:
Anthony Giovinazzo, President and CEO, Cynapsus Therapeutics Inc.
Charles Bailey, Head of Search & Evaluation, Neurosciences, Global BD & Licensing, Novartis Pharma AG
Jesse Schulman, CEO, Canbex Therapeutics
Kevin Cox, CEO, Imanova Ltd
Konrad Glund, CEO, Probiodrug AG
Patrick Doyle, CEO, KineMed, Inc.
Seth Lederman, CEO, Tonix Pharmaceuticals
Shafique Virani, Business Development, Licensing, M&A, F. Hoffmann La Roche AG
13.00
Networking Lunch
ROOM
PANORAMA A
14.00
PANORAMA B
Presenting Company TRACK A
Presenting Company TRACK B
16.00
Coffee Break
16.15
Bloomberg News Interview by Simeon Bennett
Boris L. Zaïtra, Head of Corporate M&A, F.Hoffmann-La Roche Ltd
17.00
Early Stage Investment Panel
Chaired by:
Jasper Bos, Director, MS Ventures
Featuring:
Carina Schmidt, Chief Executive Officer, Athera Biotechnologies AB
Florian Kemmerich, Chief Executive Officer, Histide AG
Frank Kalkbrenner, Head Boehringer Ingelheim Venture Fund, Boehringer Ingelheim GmbH
Ingrid Teigland Akay, Managing Director, HADEANVENTURES
Jesús Martin-Garcia, Founder and General Partner, Eclosion
Michèle Ollier, Principal, Index Ventures
Nanna Lüneborg, Investment Director, Novo Seeds, Novo A/S
18.00
Networking Reception
20.00
End of Day 1
Rare & Orphan Diseases Panel
Co-chaired by:
David Phillips, Partner, S.R.One, Limited
Lubor Gaal, Head of Europe, Search & Evaluation, Business Development, Bristol-Myers
Squibb
Featuring:
Randall Morin, Lead, Business Development Transactions, Shire Pharmaceuticals
Sten Verland, Partner, Sunstone Capital A/S
Platform Technologies & Novel Therapeutics Panel
Co-chaired by:
Esteban Pombo-Villar, COO, Oxford BioTherapeutics
Katya Smirnyagina, Partner, Capricorn Venture Partners NV
Featuring:
Malcolm Weir, Founder, Director, CEO, Heptares Therapeutics
Philippe Calais, CEO, Isarna Therapeutics GmbH
Rao Movva, Executive Director, Novartis Institutes for BioMedical Research, Inc.
BERNE
Presenting Company TRACK C
08.00
4th of March 2015
PANORAMA A
Registration & Coffee
08.30
Partnering Panel I
Co-chaired by:
Fintan Walton, CEO, PharmaVentures Ltd.
Wilder Fulford, Principal, Torreya Partners (Europe) LLC
Featuring:
Corinne Savill, Head Business Development & Licensing, Novartis Pharma AG
James Eshelby, Senior Director, Worldwide Business Development, Pfizer
Jane Atkins, Global Licensing & BD,, Director, Search & Evaluation, Takeda Pharmaceuticals International GmbH
Philippe Lopes-Fernandes, SVP, Head of Global Licensing & Business Development, EMD Serono, Inc.
Stewart Kay, Director, Transactions, GlaxoSmithKline
09.15
Partnering Panel II
Co-chaired by:
Fintan Walton, CEO, PharmaVentures Ltd.
Wilder Fulford, Principal, Torreya Partners (Europe) LLC
Featuring:
Evelyne Vuaridel, New Opportunities Officer, Europe, Debiopharm International S.A.
Jason Coloma, Global Head Venture & Innovation at Roche Partnering, F.Hoffmann La Roche AG
Lubor Gaal, Head of Europe, Search & Evaluation, Business Development, Bristol-Myers Squibb
Luca Bolliger, Vice President and Group Licensing Director, RECORDATI S.A.
Pascal Touchon, Vice President - Scientific Cooperation & Business Development, Les Laboratoires Servier
Vincent de Groot, Sr. Director, Ventures & Early Stage Collaborations, AbbVie Deutschland GmbH & Co. KG
10.00
Coffee Break
10.15
Vaccines Panel
Chaired by:
Chris Britten, Head, Business Development, Sanofi Pasteur MSD
Featuring:
Anker Lundemose, Chief Executive Officer, Mission Therapeutics
Malcolm Thomas, President and Chief Executive Officer, Arbovax Inc
William Hearl, Chief Executive Officer, Immunomic Therapeutics, Inc.
11.00
MedTech & Diagnostics Panel
Co-chaired by:
Rainer Metzger, VP Global Business Development Pharma, Qiagen
Janke Dittmer, Partner, Gilde Healthcare Partners
Featuring:
Beat Merz, Managing Director, Rockport Venture Partners
Eduardo Margallo, CEO, MedLumics
Neil Butler, Chief Executive, Spectromics
11.45
TBA
12.30
Networking Lunch
13.30
Workshop TBA
16.00
End of the Forum